{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:15:55Z","timestamp":1786994155299,"version":"build-2736575974"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T00:00:00Z","timestamp":1741046400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["metabolismjournal.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.metabol.2025.156174","type":"journal-article","created":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T11:52:36Z","timestamp":1740657156000},"page":"156174","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Differential risk assessment in persons at risk of type 2 diabetes using urinary peptidomics"],"prefix":"10.1016","volume":"167","author":[{"given":"Anja","family":"Schork","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Fritsche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erwin D.","family":"Schleicher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Peter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Heni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Stefan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reiner Jumpertz","family":"von Schwartzenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Guthoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Mischak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justyna","family":"Siwy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas L.","family":"Birkenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.metabol.2025.156174_bb0005","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00125-021-05592-3","article-title":"Prediabetes and risk of mortality, diabetes-related complications and comorbidities: umbrella review of meta-analyses of prospective studies","volume":"65","author":"Schlesinger","year":"2022","journal-title":"Diabetologia"},{"key":"10.1016\/j.metabol.2025.156174_bb0010","unstructured":"Centers for Disease Control and Prevention. National Diabetes Statistics Report website. https:\/\/www.cdc.gov\/diabetes\/data\/statistics-report\/index.html. Accessed 2024, January 16. [."},{"issue":"4","key":"10.1016\/j.metabol.2025.156174_bb0015","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1001\/jamainternmed.2020.8774","article-title":"Risk of progression to diabetes among older adults with prediabetes","volume":"181","author":"Rooney","year":"2021","journal-title":"JAMA Intern Med"},{"issue":"1","key":"10.1016\/j.metabol.2025.156174_bb0020","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41591-020-1116-9","article-title":"Pathophysiology-based subphenotyping of individuals at elevated risk for type 2 diabetes","volume":"27","author":"Wagner","year":"2021","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.metabol.2025.156174_bb0025","article-title":"Deconvoluting prediabetes: a path to understanding the origins of complications","volume":"4","author":"Wagner","year":"2023","journal-title":"Cell Rep Med"},{"issue":"1","key":"10.1016\/j.metabol.2025.156174_bb0030","doi-asserted-by":"crossref","DOI":"10.1002\/prca.202000027","article-title":"Value of urine peptides in assessing kidney and cardiovascular disease","volume":"15","author":"Latosinska","year":"2021","journal-title":"Proteomics Clin Appl"},{"issue":"11","key":"10.1016\/j.metabol.2025.156174_bb0035","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1074\/mcp.M110.001917","article-title":"Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease","volume":"9","author":"Good","year":"2010","journal-title":"Mol Cell Proteomics"},{"issue":"4","key":"10.1016\/j.metabol.2025.156174_bb0040","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S2213-8587(20)30026-7","article-title":"Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial","volume":"8","author":"Tofte","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"10.1016\/j.metabol.2025.156174_bb0045","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ijcard.2014.07.014","article-title":"Left ventricular diastolic function in relation to the urinary proteome: a proof-of-concept study in a general population","volume":"176","author":"Zhang","year":"2014","journal-title":"Int J Cardiol"},{"issue":"11","key":"10.1016\/j.metabol.2025.156174_bb0050","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1097\/HJH.0b013e32833d81b7","article-title":"Urinary proteomic diagnosis of coronary artery disease: identification and clinical validation in 623 individuals","volume":"28","author":"Delles","year":"2010","journal-title":"J Hypertens"},{"issue":"5\u20136","key":"10.1016\/j.metabol.2025.156174_bb0055","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1002\/prca.201400195","article-title":"Urinary proteomic biomarkers to predict cardiovascular events","volume":"9","author":"Brown","year":"2015","journal-title":"Proteomics Clin Appl"},{"issue":"12","key":"10.1016\/j.metabol.2025.156174_bb0060","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1007\/s00125-017-4407-z","article-title":"Non-alcoholic fatty liver disease and impaired proinsulin conversion as newly identified predictors of the long-term non-response to a lifestyle intervention for diabetes prevention: results from the TULIP study","volume":"60","author":"Schmid","year":"2017","journal-title":"Diabetologia"},{"issue":"9","key":"10.1016\/j.metabol.2025.156174_bb0065","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.2337\/diacare.22.9.1462","article-title":"Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp","volume":"22","author":"Matsuda","year":"1999","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.metabol.2025.156174_bb0070","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1007\/s00592-016-0930-5","article-title":"A novel insulin sensitivity index particularly suitable to measure insulin sensitivity during gestation","volume":"53","author":"Wagner","year":"2016","journal-title":"Acta Diabetol"},{"issue":"1","key":"10.1016\/j.metabol.2025.156174_bb0075","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1021\/pr800401m","article-title":"Quantitative urinary proteome analysis for biomarker evaluation in chronic kidney disease","volume":"8","author":"Jantos-Siwy","year":"2009","journal-title":"J Proteome Res"},{"issue":"7","key":"10.1016\/j.metabol.2025.156174_bb0080","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/elps.201300327","article-title":"Comparison of CE-MS\/MS and LC-MS\/MS sequencing demonstrates significant complementarity in natural peptide identification in human urine","volume":"35","author":"Klein","year":"2014","journal-title":"Electrophoresis"},{"issue":"6","key":"10.1016\/j.metabol.2025.156174_bb0085","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.clinbiochem.2012.09.025","article-title":"Technical aspects and inter-laboratory variability in native peptide profiling: the CE-MS experience","volume":"46","author":"Mischak","year":"2013","journal-title":"Clin Biochem"},{"issue":"18\u201319","key":"10.1016\/j.metabol.2025.156174_bb0090","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1002\/elps.201900091","article-title":"Peptidomics and proteomics based on CE-MS as a robust tool in clinical application: the past, the present, and the future","volume":"40","author":"Latosinska","year":"2019","journal-title":"Electrophoresis"},{"issue":"23","key":"10.1016\/j.metabol.2025.156174_bb0095","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26237260","article-title":"Reproducibility evaluation of urinary peptide detection using CE-MS","volume":"26","author":"Mavrogeorgis","year":"2021","journal-title":"Molecules"},{"issue":"4","key":"10.1016\/j.metabol.2025.156174_bb0100","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/prca.200900189","article-title":"Comprehensive human urine standards for comparability and standardization in clinical proteome analysis","volume":"4","author":"Mischak","year":"2010","journal-title":"Proteomics Clin Appl"},{"key":"10.1016\/j.metabol.2025.156174_bb0105","article-title":"GDF-15 improves the predictive capacity of Steatotic liver disease non-invasive tests for incident morbidity and mortality risk for cardio-renal-metabolic diseases and malignancies","volume":"156047","author":"Kokkorakis","year":"2024","journal-title":"Metabolism"},{"issue":"2","key":"10.1016\/j.metabol.2025.156174_bb0110","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/s43587-023-00565-0","article-title":"Plasma proteomic profiles predict future dementia in healthy adults","volume":"4","author":"Guo","year":"2024","journal-title":"Nat Aging"},{"key":"10.1016\/j.metabol.2025.156174_bb0115","unstructured":"Kuhn M. caret: Classification and Regression Training. Astrophysics Source Code Library. 2015:ascl:1505.003."},{"issue":"1","key":"10.1016\/j.metabol.2025.156174_bb0120","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s12933-023-01923-3","article-title":"Clusters of prediabetes and type 2 diabetes stratify all-cause mortality in a cohort of participants undergoing invasive coronary diagnostics","volume":"22","author":"Prystupa","year":"2023","journal-title":"Cardiovasc Diabetol"},{"issue":"12","key":"10.1016\/j.metabol.2025.156174_bb0125","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/nrneph.2016.145","article-title":"The impact of insulin resistance on the kidney and vasculature","volume":"12","author":"Artunc","year":"2016","journal-title":"Nat Rev Nephrol"},{"issue":"11","key":"10.1016\/j.metabol.2025.156174_bb0130","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/S2213-8587(23)00235-8","article-title":"Mechanisms of weight loss-induced remission in people with prediabetes: a post-hoc analysis of the randomised, controlled, multicentre prediabetes lifestyle intervention study (PLIS)","volume":"11","author":"Sandforth","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"10.1016\/j.metabol.2025.156174_bb0135","doi-asserted-by":"crossref","first-page":"362","DOI":"10.2337\/db22-0441","article-title":"Lower hepatic fat is associated with improved insulin secretion in a high-risk prediabetes subphenotype during lifestyle intervention","volume":"72","author":"Wagner","year":"2023","journal-title":"Diabetes"},{"issue":"8","key":"10.1016\/j.metabol.2025.156174_bb0140","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1111\/dom.14733","article-title":"Eight weeks of empagliflozin does not affect pancreatic fat content and insulin secretion in people with prediabetes","volume":"24","author":"Hummel","year":"2022","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"10.1016\/j.metabol.2025.156174_bb0145","doi-asserted-by":"crossref","first-page":"398","DOI":"10.2337\/dc21-1136","article-title":"Empagliflozin improves insulin sensitivity of the hypothalamus in humans with prediabetes: a randomized, double-blind, placebo-controlled, phase 2 trial","volume":"45","author":"Kullmann","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2025.156174_bb0150","doi-asserted-by":"crossref","unstructured":"Jumpertz von Schwartzenberg R, Stefan N, Wagner R, Guthoff M, Sandforth A, Icks A, et al. SGLT2 inhibition in addition to lifestyle intervention and risk for complications in subtypes of patients with prediabetes - a randomized, placebo controlled, multi-center trial (LIFETIME) \u2013 rationale, methodology and design. medRxiv. 2023:2023.11.18.23298622.","DOI":"10.1101\/2023.11.18.23298622"},{"issue":"3","key":"10.1016\/j.metabol.2025.156174_bb0155","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1093\/ndt\/gfx068","article-title":"Cost-effectiveness of screening type 2 diabetes patients for chronic kidney disease progression with the CKD273 urinary peptide classifier as compared to urinary albumin excretion","volume":"33","author":"Critselis","year":"2018","journal-title":"Nephrol Dial Transplant"},{"issue":"11","key":"10.1016\/j.metabol.2025.156174_bb0160","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.2337\/dc22-1157","article-title":"Dapagliflozin improves the urinary proteomic kidney-risk classifier CKD273 in type 2 diabetes with albuminuria: a randomized clinical trial","volume":"45","author":"Curovic","year":"2022","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.metabol.2025.156174_bb0165","doi-asserted-by":"crossref","DOI":"10.3390\/ph16091298","article-title":"Prognosis and personalized in silico prediction of treatment efficacy in cardiovascular and chronic kidney disease: a proof-of-concept study","volume":"16","author":"Jaimes Campos","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"issue":"3","key":"10.1016\/j.metabol.2025.156174_bb0170","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1159\/000481375","article-title":"Dynamics of glucose metabolism after kidney transplantation","volume":"42","author":"Guthoff","year":"2017","journal-title":"Kidney Blood Press Res"},{"issue":"10","key":"10.1016\/j.metabol.2025.156174_bb0175","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1111\/tri.13967","article-title":"Dynamics of glucose metabolism after liver transplantation: prediabetes as a window of opportunity for patient survival and long-term kidney function","volume":"34","author":"Grottenthaler","year":"2021","journal-title":"Transpl Int"},{"key":"10.1016\/j.metabol.2025.156174_bb0180","unstructured":"https:\/\/www.dzd-ev.de\/en\/press\/press-releases\/press-releases-archive\/press-releases-2021\/prediabetes-subtypes-identified\/index.html [Accessed 2024, November 5] [."}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049525000435?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049525000435?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T20:36:27Z","timestamp":1743971787000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049525000435"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":36,"alternative-id":["S0026049525000435"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2025.156174","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Differential risk assessment in persons at risk of type 2 diabetes using urinary peptidomics","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2025.156174","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"156174"}}